Implantable neuromodulation technology developer Neuspera Medical announced today that Steffen Hovard joined the company as CEO.
Hovard most recently served as president of Coloplast’s interventional urology arm. He had leadership responsibilities across four business areas within urological devices. At Coloplast, he oversaw 900 employees across 19 countries.
According to a news release, Hovard also serves as a board member for a number of medical device companies.
“I am delighted to have Steffen join and lead Neuspera as we look to bring our therapy platform to patients struggling with debilitating conditions such as UUI [urinary urgency incontinence],” said Mudit Jain of Treo Ventures, an investor in Neuspera. “He is an accomplished executive with an impressive record of leading multiple functions and driving significant growth in the urology space.”
Hovard joins just after Neuspera began enrollment for the second phase of its U.S. pivotal clinical trial, SANS-UUI. The study is evaluating the safety and efficacy of Nuvella for treating UUI, a symptom of overactive bladder (OAB).
“I am excited to join Neuspera at this important time as the company builds momentum and clinical evidence for the Nuvella system,” Hovard said. “Sacral neuromodulation (SNM) is a proven therapy for the treatment of UUI which can significantly improve quality of life in patients suffering from this condition. Nuvella is the first sacral neuromodulation device that offers an ultra-miniaturized option, which aims to provide a better patient experience and greater procedural versatility.
“I look forward to working with a world-class team to bring this important technology to market.”
What does Neuspera do?
San Jose, California-based Neuspera develops its proprietary mid-field powering technology. Its design allows for devices that are significantly smaller and implanted deeper to provide treatment for chronic diseases. The company said the platform offers new and potentially earlier treatment options that are less invasive and more adaptable.
The company raised a $26 million Series B funding round in 2018. It picked up a $65 million Series C — co-led by Treo — in July 2021.
